Extended Data Fig. 6: Evidence of immune activation during treatment with spartalizumab in combination with dabrafenib and trametinib. | Nature Medicine

Extended Data Fig. 6: Evidence of immune activation during treatment with spartalizumab in combination with dabrafenib and trametinib.

From: Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

Extended Data Fig. 6

a, Analysis of intratumoral density of CD8+ cells for available paired tumor biopsy specimens (n = 9) at baseline and on treatment using exploratory H-score analysis. Scale bars = 100 μm. b, Modulation of plasma IFN-γ following treatment with spartalizumab plus dabrafenib plus trametinib. Of the 27 independent plasma specimens analyzed, 25 showed elevated IFN-γ levels on treatment, while the other 2 showed a slight decrease. Box plot shows median, first and third quartiles (boxes), and range up to 1.5 times IQR from the bounds of the box [whiskers]. Points beyond 1.5 times IQR from the bounds of the box are plotted individually. Baseline, 1.78 (1.06-2.37) [1.06-4.19]. On treatment, 6.08 (3.65-7.88) [1.69-10.51]. IFN, interferon; IHC, immunohistochemistry; IQR, interquartile range.

Back to article page